Can Investors Gain from the New Age in Medical Testing?

A new age in medical testing may be dawning. Improvements in genetic analysis could revolutionize the way disease is treated. Can investors in participating companies like Illumina, Myriad Genetics and Bio-Rad Labs gain from this momentous transformation?

Feb 6, 2014 at 6:30PM

We might be entering a new age in medical testing. Molecular-level diagnostics, or tests based on the role genes play in human diseases, looks to provide earlier detection and more effective treatments for the most deadly conditions. Can investors profit from this diagnostic testing revolution via sector participants such as Illumina (NASDAQ:ILMN), Myriad Genetics (NASDAQ:MYGN), or Bio-Rad Laboratories (NYSE:BIO)? Let's take a look.

A leading company at an enthusiastic price
Illumina is a leader in the field of genetic analysis. Providing tools that scientists use to breakdown and analyze genes, the company sells to medical research centers, biotechs, and pharmaceutical companies.

The more medical research delves deeper into the mystery of the gene, the more Illumina gains. In its recently completed fiscal year, revenues jumped 24% and adjusted net income climbed 19% from the prior period. For the current year, the company is projecting an additional 15% to 17% rise in revenues with adjusted earnings per share growth of over 10%.

New products will also help boost demand. The company's recently introduced HiSeq X Ten Sequencing System could be a big seller. The HiSeq X Ten delivers massive amounts of gene information quicker and at a significantly lower price, about 10% of past cost. Eric Lander, founding director of the Broad Institute and a professor of biology at MIT, believes that "over the next few years, we have an opportunity to learn as much about the genetics of human disease as we have learned in the history of medicine." This achievement is due to products like Illumina's HiSeq X Ten. 

While Illumina appears to have tremendous prospects, investors may have already factored much of the good news into the stock. Currently trading at over 60 times forward earnings, basically net income plus non-cash charges such as depreciation and amortization adjusted for expected capital expenditures, the company's shares may be priced too enthusiastically and could be vulnerable to any kind of disappointment.

Investor optimism despite recent troubles
Bio-Rad Laboratories is a long-time, well-entrenched participant in the medical diagnostics sector. While not embedded in technologically advanced markets like Illumina, Bio-Rad does have a leading position in its core lab products and systems markets.

The company has been facing some recent headwinds, however. Top-line growth has been sluggish with profits under pressure. Bio-Rad's latest quarterly revenues increased a slight 1.3% year-over-year and net income fell to a loss of $7 million compared to income of $42.6 million a year earlier. Higher employee costs from a series of acquisitions and expenses associated with a major computer system upgrade were the main reasons for the profit falloff. 

Bio-Rad has also encountered some administrative troubles. Currently being investigated for violations of the Foreign Corrupt Practices Act, the company is in settlement talks, but the timing and ultimate price of a resolution is still unknown. Bio-Rad additionally announced the identification of some accounting errors dating back to 2008. While the figures involved don't appear material, the news was disquieting.

In a sign of investor enthusiasm for diagnostic testing product companies as a whole, Bio-Rad's weak sales growth and administrative turmoil have surprisingly not distressed its shares. Priced at over 20 times forward earnings, it appears the stock market has already anticipated improved performance.

Caution trumping current growth
Myriad Genetics might be the most interestingly positioned diagnostic testing company. A leader in providing individual patient tests that assess the risk of developing a disease based on gene profile, demand for the company's products has soared.

In its most recent quarter, revenues increased an impressive 52% year over year and earnings per share jumped a whopping 89%. Requests for Myriad's BRACAnalysis test, a genetic review that confirms the presence of gene mutations responsible for the majority of breast and ovarian cancers, produced about 74% of all sales. 

The company's strong performance has been overshadowed by a couple of major setbacks, however. A recent U.S. government proposal to cut BRACAnalysis reimbursements stunned investors. Though government payments make up only about 10% of BRAC testing sales, the reduction suggests health insurance payers might also look to reduce fees. Additional pricing pressures will be applied thanks to last summer's adverse U.S. Supreme Court decision that invalidated some of Myriad 's gene patents. Myriad will likely now face determined and aggressive competition in the patient genetic testing market.

In spite of the reversals, the company looks ready to deliver a multitude of new tests. Myriad recently launched a product that detects a possible gene indicator for increased colon cancer risk. Another test introduction relates to a highly significant predictor for patients with early stage lung cancer. Promising gene-based analytic procedures for breast, prostate, and melanoma cancers are also being developed. 

Can the growth in genetic testing generally and Myriad's onslaught of new procedures outpace potential pricing pressures? Investors appear skeptical. Currently valued at only around 16 times forward earnings, the company seems priced at a noticeably cautious discount to other industry participants. The company could potentially offer some share price upside if results aren't as dire as expected, however.

We may be on the cusp of a new age in medical testing. Increased capabilities in gene analysis could initiate previously inconceivable advancements in drug discovery and patient health. How can investors benefit? While the sector's future is certainly bright, excessive enthusiasm may have pushed share prices dangerously high. Patiently waiting for opportunistic price pullbacks in well regarded stocks like Illumina and Bio-Rad Laboratories or holding out for reimbursement rate stability at besieged Myriad Genetics may be the surest way investors can profit from this momentous testing revolution.

Another great stock idea for 2014
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Bob Chandler has no position in any stocks mentioned. The Motley Fool recommends Illumina. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers